Search for content, post, videos

Positive preclinical results from Spago Nanomedical

Tumorad Emil Aaltonen
Spago Nanomedical has announced new results which show that the company's candidate drug Tumorad significantly reduces tumor growth and prolongs survival in a preclinical model for colorectal cancer. Together with previously communicated clinical and preclinical results, the new results provide a
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.